Plasma Free Fatty Acids in Risk Assessment of Sepsis in the Emergency Department: A Prospective Pilot Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01530854|
Recruitment Status : Completed
First Posted : February 10, 2012
Last Update Posted : March 17, 2017
|Condition or disease|
The long term objective of this study is to investigate the mechanism by which plasma free fatty acids (FFAs) contribute to the progression of sepsis severity in infectious patients presenting to the Emergency Department. In the present study, pilot data will be generated to validate our hypothesis that elevated free fatty acids are related to outcome in sepsis.
We will examine our hypotheses with the following specific aims:
- To determine if plasma FFA levels are related to severity of illness in patients with sepsis presenting to the Emergency Department.
- To study the prognostic value of plasma FFA levels at predicting future morbidity and mortality in patients with sepsis presenting to the Emergency Department.
|Study Type :||Observational|
|Actual Enrollment :||74 participants|
|Official Title:||Plasma Free Fatty Acids in Risk Assessment of Sepsis in the Emergency Department: A Prospective Pilot Study|
|Study Start Date :||February 2008|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||January 2012|
- Disposition: Admission to hospital or discharge home [ Time Frame: within 48 h ]
- Hospital length-of-stay [ Time Frame: 30 days ]
- All cause mortality [ Time Frame: 30 days ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01530854
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|Principal Investigator:||Rakesh Engineer, MD||The Cleveland Clinic|
|Principal Investigator:||Caitlin W Hicks, BA||The Cleveland Clinic|